Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Name: Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Published: 2013
License: Public Domain

Celgene · 2013

ClinicalTrials.gov · Datasets · License: Public Domain · 2013

Open Source ↗

acute-myeloid-leukemia

hematologic neoplasms, acute myeloid leukemia, aml, myelodysplastic syndrome, mds, hematologic malignancies, idh2, phase i, phase ii, ag-221, relapse aml, refractory aml

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 828725
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.